CAM
ALNY icon

Congress Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Congress Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80M Sell
265,701
-20,038
-7% -$6.04M 0.49% 81
2026
Q1 		$94.5M Buy
285,739
+16,500
+6% +$5.61M 0.68% 46
2025
Q4 		$107M Buy
269,239
+150,439
+127% +$66.6M 0.75% 43
2025
Q3 		$54.2M Buy
+118,800
New +$48.4M 0.36% 105

Other funds holding ALNY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Congress Asset Management's ALNY Position: Q2 2026 in Review

Congress Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 7% in Q2 2026, selling an estimated $6.04M and leaving 265,701 shares worth $80M. The position accounts for 0.49% of the portfolio, ranked #81.

Congress Asset Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $107M in Q4 2025. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Congress Asset Management held 265,701 shares of Alnylam Pharmaceuticals worth $80M as of Q2 2026.
  • Congress Asset Management sold 20,038 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.04M.
  • Alnylam Pharmaceuticals made up 0.49% of Congress Asset Management's portfolio in Q2 2026, its #81 holding.
  • Congress Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Congress Asset Management's Alnylam Pharmaceuticals position peaked at $107M in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.